CELU Stock Overview
A clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Celularity Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.64 |
| 52 Week High | US$5.22 |
| 52 Week Low | US$1.00 |
| Beta | 0.58 |
| 1 Month Change | 5.81% |
| 3 Month Change | -21.90% |
| 1 Year Change | -60.95% |
| 3 Year Change | -98.46% |
| 5 Year Change | -98.34% |
| Change since IPO | -98.33% |
Recent News & Updates
Recent updates
Celularity Inc.'s (NASDAQ:CELU) Business And Shares Still Trailing The Industry
Feb 21
Celularity Inc. (NASDAQ:CELU) Held Back By Insufficient Growth Even After Shares Climb 80%
Feb 14Celularity appoints Adrian Kilcoyne as chief medical officer
Oct 03Celularity falls after announcing fund raising deal
Sep 15Celularity falls 10% on deal for $150M common stock offering
Sep 08Celularity begins phase 1/2a trial for cell therapy CYNK-101 to treat cancers
Jul 27Shareholder Returns
| CELU | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 18.0% | 1.3% | 5.8% |
| 1Y | -61.0% | -11.3% | 4.8% |
Return vs Industry: CELU underperformed the US Biotechs industry which returned -11.3% over the past year.
Return vs Market: CELU underperformed the US Market which returned 4.8% over the past year.
Price Volatility
| CELU volatility | |
|---|---|
| CELU Average Weekly Movement | 18.6% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 7.7% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: CELU's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CELU's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of US stocks.
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 120 | Bob Hariri | www.celularity.com |
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. The company operates through Cell Therapy, Degenerative Disease, and BioBanking segments. Its lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn’s disease.
Celularity Inc. Fundamentals Summary
| CELU fundamental statistics | |
|---|---|
| Market cap | US$36.87m |
| Earnings (TTM) | -US$35.05m |
| Revenue (TTM) | US$48.20m |
0.8x
P/S Ratio-1.1x
P/E RatioIs CELU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CELU income statement (TTM) | |
|---|---|
| Revenue | US$48.20m |
| Cost of Revenue | US$17.26m |
| Gross Profit | US$30.95m |
| Other Expenses | US$66.00m |
| Earnings | -US$35.05m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.56 |
| Gross Margin | 64.20% |
| Net Profit Margin | -72.72% |
| Debt/Equity Ratio | 246.6% |
How did CELU perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/14 09:09 |
| End of Day Share Price | 2025/04/11 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Celularity Inc. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| Thomas Shrader | BTIG |
| Swayampakula Ramakanth | H.C. Wainwright & Co. |